Skip to content
What's on

Oligonucleotide therapeutics: challenges and opportunities

Online event

Overview

This Royal Society meeting will seek to explore the opportunities and existing challenges of oligonucleotide-based therapies as a platform. Speakers will discuss overcoming barriers in manufacturing and stability of molecules, and the delivery, and efficacy and efficiency of oligonucleotide-based therapies. 

Carlton House Terrace

Background

This meeting will bring together key stakeholders from across the sector to highlight the emerging technologies in the field and explore opportunities around the use of oligonucleotides as therapeutic agents, including siRNA, antisense, and aptamers.  

Speakers will also outline some of the key challenges such as targeted delivery, the balance of efficacy and efficiency, and manufacturing that must be addressed if these wide ranging therapeutics are to be successful.

The conference will conclude with a panel discussion on the future of Oligonucleotide therapeutics.

About the conference series

Supported by AstraZeneca, the meeting will form part of the Royal Society’s Transforming our future conferences in the life sciences. These meetings are unique, high-level events that address the scientific and technical challenges of the next decade. Each conference features cutting edge science from industry and academia and brings together leading experts from the scientific community, including regulatory, charity and funding bodies.

Event organisers

Select an organiser for more information

Schedule of talks

08 February

13:00-14:20

Overview of the field

3 talks Show detail Hide detail

13:05-13:30 Overview of the potential for oligonucleotide therapies

13:30-13:55 Basic chemistry of Oligonucleotides

13:55-14:20 Challenges and opportunities in targeted delivery and distribution

Professor Anastasia Khvorova, University of Massachusetts Medical School

Show speakers

14:20-14:30

Break

14:30-15:45

Challenges in development

5 talks Show detail Hide detail

14:30-14:45 Balancing safety and efficacy

Professor Anne Willis, MRC Toxicology Unit, UK

Show speakers

14:45-15:00 Challenges and solutions associated with scale up and manufacturing

15:00-15:15 Building partnerships

15:15-15:30 Regulatory paths for oligotherapeutics

15:30-15:45 Q&A panel

15:45-16:00

Break

16:00-16:50

Panel: where is the field going?

Related events

Oligonucleotide therapeutics: challenges and opportunities

This Royal Society meeting will seek to explore the opportunities and existing challenges of oligonucleotide-based therapies as a platform.

other
Was this page useful?
Thank you for your feedback
Thank you for your feedback. Please help us improve this page by taking our short survey.